Elucidation of an SRE-1/SREBP-independent cellular pathway for LDL-receptor regulation: From the cell surface to the nucleus

Future Cardiology

Volumn 2, Issue 5, 2006, Pages 605-612

  Liu, Jingwen ^a   Briggs, Michael R ^b   Kraemer, Fredric B ^a,c  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Hyperlipidemia; LDL receptor; Oncostatin M; Sterol independent regulatory element

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; CCAAT ENHANCER BINDING PROTEIN BETA; CYTOKINE; EARLY GROWTH RESPONSE FACTOR 1; GW 707; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; MITOGEN ACTIVATED PROTEIN KINASE; ONCOSTATIN M; RECOMBINANT CYTOKINE; RECOMBINANT ONCOSTATIN M; STEROL REGULATORY ELEMENT 1; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CELL NUCLEUS; CELL SURFACE; CHOLESTEROL BLOOD LEVEL; CYCLIC AMP RESPONSIVE ELEMENT; DOSE RESPONSE; DRUG ACTIVITY; DRUG POTENTIATION; GENETIC TRANSCRIPTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID STORAGE; LIVER CELL; NEGATIVE FEEDBACK; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION;

EID: 33749546692     PISSN: 14796678     EISSN: 17448298     Source Type: Journal    
DOI: 10.2217/14796678.2.5.605     Document Type: Review

References (48)

1. Grundy SM: Statin trials and goals of cholesterol-lowering therapy. Circulation 97, 1436-1439 (1998).
2. Ansell BJ, Watson KE, Fogelman AM: An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines. National Cholesterol Education Program. JAMA 282, 2051-2057 (1999).
3. Brown MS, Goldstein JL: A receptor-mediated pathway for cholesterol homeostasis. Science 232, 34-47 (1986).
4. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343, 425-430 (1990).
5. Brown MS, Goldstein JL: A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc. Natl Acad. Sci. USA 96, 11041-11048 (1999).
6. Sudhof TC, van der Westhuyzen DR, Goldstein JL, Brown MS, Russell DW: Three direct repeats and a TATA-like sequence are required for regulated expression of the human low-density lipoprotein receptor gene. J. Biol. Chem. 262, 10773-10779 (1987).
7. Dawson PA, van der Westhuyzen DR, Sudhof TC, Brown MS, Goldstein JL: Sterol-dependent repression of low-density lipoprotein receptor promoter mediated by 16-base pair sequence adjacent to binding site for transcription factor Sp1. J. Biol. Chem. 263, 3372-3379 (1988).
8. Sudhof TC, Russell DW, Brown MS, Goldstein JL: 42 bp element from LDL receptor gene confers end-product repression by sterols when inserted into viral TK promoter. Cell 48, 1061-1069 (1987).
9. Briggs MR, Yokoyama C, Wang X, Brown MS, Goldstein JL: Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. J. Biol. Chem. 268, 14490-14496 (1993).
10. Wang X, Briggs MR, Yokoyama C, Goldstein JL, Brown MS: Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter II. Purification and characterization. J. Biol. Chem. 268, 14497-14504 (1993).
11. Yokoyama C, Wang X, Briggs MR et al.: SREBP-1, a basic-helix-loop-helix-leucine zipper protein that controls transcription of the low density lipoprotein receptor gene. Cell 75, 187-197 (1993).
12. Hua X, Yokoyama C, Wu J et al.: SREBP-2, a second basic-helix-loop-helix-leucine zipper protein that stimulates transcription by binding to a sterol regulatory element. Proc. Natl Acad. Sci. USA 90, 11603-11607 (1993).
13. Norturfft A, DeBose-Boyd RA, Scheek S, Goldstein JL, Brown MS: Sterols regulate cycling of SREBP cleavage-activating protein (SCAP) between endoplasmic reticulum and Golgi. Proc. Natl Acad. Sci. USA 96, 11235-11240 (1999).
14. Yang T, Goldstein JL, Brown MS: Overexpression of membrane domain of SCAP prevents sterols from inhibiting SCAP/SREBP exit from endoplasmic reticulum. J. Biol. Chem. 275, 29881-29886 (2000).
15. Nohturfft A, Yabe D, Goldstein JL, Brown MS, Espenshade PJ: Regulated step in cholesterol feedback localized to budding of SCAP from ER membrane. Cell 102, 315-323 (2000).
16. Wang X, Sato R, Brown MS, Hua X, Goldstein JL: SREBP-1, a membrane bound transcription factor released by sterol-regulated proteolysis. Cell 77, 53-62 (1994).
17. Sanchez HB, Yieh L, Osborne TF: Cooperation by sterol regulatory element-binding protein and Sp1 in sterol regulation of low density lipoprotein receptor gene. J. Biol. Chem. 270, 1161-1169 (1995).
18. Rudling M, Norstedt G, Olivecrona H, Rethner E, Gustafsson J, Angelin B: Importance of growth hormone for the induction of hepatic low density lipoprotein receptors. Proc. Natl Acad. Sci. USA. 89, 6983-6987 (1992).
19. Pak YK, Kanuck MP, Berrios D, Briggs MR, Cooper AD, Ellsworth JL: Activation of LDL receptor gene expression in HepG2 cells by hepatocyte growth factor. J. Lipid Res. 37, 985-998 (1996).
20. Stopeck AT, Nicholson AC, Mancini FP, Haijar DP: Cytokine regulation of low-density lipoprotein receptor gene transcription in HepG2 cells. J. Biol. Chem. 268, 17489-17494 (1993).
21. Ruan XZ, Moorhead JF, Tao JL et al: Mechanisms of dysregulation of low-density lipoprotein receptor expression in vascular smooth muscle cells by inflammatroy cytokines. Arterioscler. Thromb. Vasc. Biol. 26, 1150-1155 (2006).
22. Tanaka M, Miyajima A: Oncostatin M, a multifunctional cytokine. Rev. Physiol. Pharmacol. 1007, 003-0013 (2003).
23. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F: Principles of interleukin (IL)-6-type cytokines signalling and its regulation. Biochem. J. 374, 1-20 (2003).
24. Grove RI, Mazzucco CE, Allegretto N et al. Macrophages-derived factors increase low-density lipoprotein uptake and receptor number in cultured human liver cells. J. Lipid Res. 32, 1889-1897 (1991).
25. Grove RI, Mazzucco CE, Radka SF, Shoyab M: Oncostatin M upregulates LDL receptor in HepG2 cells by a novel mechanism. J. Biol. Chem. 266, 18194-18199 (1992).
26. Liu J, Grove RI, Vestal RE: Oncostatin M activates the LDL receptor transcription in sterol-repressed liver cells. Cell Growth Differ. 5, 1333-1338 (1994).
27. Liu J, Streiff R, Zhang YL, Vestal RE, Spence MJ, Briggs MR: Novel mechanism of transcriptional activation of hepatic LDL receptor by oncostatin M. J. Lipid Res. 38, 2035-2048 (1997).
28. Gearing DP, Bruce AG: Oncostatin M binds the high-affinity leukemia inhibitory factor receptor. New Biol. 4, 61-65 (1991).
29. Gearing DP, Comeau MR, Friend DJ et al.: The IL-6 signal transducer, gp130: an oncostatin M receptor and affinity converter for the LIF receptor. Science 255, 1434-1437 (1992).
30. Liu J, Modrell B, Aruffo A et al.: Interleukin-6 signal transducer gp130 mediates oncostatin M signal. J. Biol. Chem. 267, 16763-16766 (1992).
31. Mosley B, Imus CD, Friend D et al.: Dual oncostatin M receptors: cloning and characterization of an alternative signaling subunit conferring oncostatin M-specific receptor activation. J. Biol. Chem. 271, 32635-32643 (1996).
32. 0 growth-arrested mouse mammary epithelial cells and in involating mouse mammary gland. J. Biol. Chem. 275, 29123-29131 (2000).
33. Zhang F, Li C, Halfter H, Liu J: Delineating an oncostatin M-activated STAT3 signaling pathway that coordinates the expression of genes involved in cell cycle regulation and extracellular matrix deposition of MCF-7 cells. Oncogene 22, 894-905 (2003)
34. Zhang Z, Fuentes NL, Fuller GM: Characterization of the IL-6 responsive element in the γ fibrinogen gene promoter. J. Biol. Chem. 270, 24287-24291 (1995).
35. Li C, Kraemer FB, Ahlborn TE, Liu J: Induction of low density lipoprotein receptor (LDLR) transcription by oncostatin M is mediated by the extracellular signal-regulated kinase signaling pathway and the repeat 3 element of the LDLR promoter. J. Biol. Chem. 274, 6747-6753 (1999).
36. Boing I, Stross C, Radtke S, Lippok BE, Heinrich PC, Hermanns HM: Oncostatin M-induced activation of stress-activated MAP kinases depends on tyrosine 861 in the OSM receptor and requires Jak1 but not Src kinases. Cell signal 18, 50-61 (2006).
37. Roth G, Kotzka J, Kremer L et al.: MAP kinase Erk1/2 phosphorylate sterol regulatory element-binding protein (SREBP)-1a at serine 117 in vitro. J. Biol. Chem. 275, 33302-33307 (2000).
38. Abidi P, Zhang F, Li C, Liu J: Blockage of the ERK signaling pathway abrogates the SCAP ligand-induced transcriptional activation of the LDL receptor gene in HepG2 cells. Int. J. Mol. Med. 16, 779-785 (2005).
39. Liu J, Ahlborn TE, Briggs MR, Kraemer FB: Identification of a novel sterol-independent regulatory element in the human low density lipoprotein receptor promoter. J. Biol. Chem. 275, 5214-5221 (2000).
40. Zhang F, Ahlborn TE, Li C, Kraemer FB, Liu J: Identification of Egr1 as the oncostatin M-induced transcription activator that binds to the sterol-independent regulatory element of the human LDL receptor promoter. J. Lipid Res. 43, 1477-1485 (2002).
41. Christy B, Lau L, Nathans D: A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with 'zinc finger' sequences. Proc. Natl Acad. Sci. USA 85, 797-799 (1988).
42. Nathans D, Christy B: DNA binding site of the growth factor-inducible protein Zif268. Proc. Natl Acad. Sci. USA 86, 8737-8741 (1989).
43. Zhang F, Lin M, Abidi P, Thiel G, Liu J: Specific interaction of Egr1 and c/EBPβ leads to the transriptional activation of the human low density lipoprotein receptor gene. J. Biol. Chem. 278, 44246-44254 (2003).
44. Zhou Y, Zhang F, Abidi P, Lin M, Thiel G, Liu J: Blockage of oncostatin M-induced LDL receptor gene transcription by a dominant-negative mutant of c/EBPβ. Biochem. J. 396, 101-108 (2006).
45. Liu J, Zhang F, Li C, Lin M, Briggs MR: Synergistic activation of human LDL receptor expression by SCAP ligand and cytokine oncostatin M. Arterioscler. Throm. Vasc. Biol. 23, 90-96 (2003).
46. Kong WJ, Abidi P, Jiang JD, Liu J: In vivo activities of cytokine oncostatin M in the regulation of plasma lipid levels. J. Lipid Res. 46, 1163-1171 (2005).
47. Kamiya A, Kinoshita T, Ito Y et al.: Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer. EMBO J 18, 2127-2136 (1999).
48. Nakamura M, Nonaka H, Saito H, Tanaka M, Miyajima A: Hepatocyte proliferation and tissue remodeling is impaired after liver injury in oncostatin M receptor knockout mice. Hepatology 39, 635-644 (2004).